If you are a pharmacist, nurse practitioner, or other health care professional providing comprehensive medication management for individuals living with psychiatric disorders, we invite you to participate in this course.
You will proceed through the following steps to satisfactorily complete this course:
Sign in (or create a FREE account).
Register for this course.
Review the full content of the activity and reflect upon its teachings.
Complete the post-test at the end of the activity no later than the closing activity date.
Complete the evaluation at the end of the activity.
If necessary, complete the post-test retest no later than the closing activity date.
Receive a passing grade (70%).
Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor.
Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
but most features work with Internet Explorer 10+, or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat or FoxIt
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information and Disclosures
Sandra Mullen, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
VCU Health Systems
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Off-label use of stimulants, antipsychotics,
alpha-agonists, and mood stabilizers in children and adolescents.
ACPE #0284-0000-22-007-H01-P (Knowledge) Author: Sandra Mullen, PharmD, BCPP Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Explain the use of common rating scales for research, diagnosis, and management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
Fragile X Syndrome
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Continuing Education Credit and Disclosures
Activity Dates:01/01/2022 - 12/31/2023 ACPE Contact Hours: 1 ACPE Number: 0284-0000-22-007-H01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Megan J. Ehret, PharmD, BCPP, MS
BCPP Program Director
University of Maryland
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Clayton D. English, PharmD, BCPS, BCPP, BCGP
Albany College of Pharmacy and Health Sciences
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: University of Florida-Medication
Non-Financial Interests: Drug Utilization Review Board-Vermont State Medicaid, Board Member
Stephanie Nichols, PharmD, BCPP, BCPS, FCCP
Associate Professor of Pharmacy Practice
University of New England
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: I am a member of the New England
Public Advisory Council (affiliated with the Institute for Clinical and Economic Review)., I am a consultant
for SAMHSA grant funded Opioid Response Network.
Educational Grants, Research Grants or Contracts: Shire sponsored the development of an Adult
ADHD toolkit, through the American Association of Family Physicians. I was compensated $2,000
for my time and participation in the development of said toolkit. Feb - May 2019, A colleague and I
have received a grant for $21,000 by the State of Maine to develop and execute naloxone and stigma
education for pharmacy professionals in Maine. July 2019 - July 2020
Non-Financial Interests: Maine Independent Clinical Information Service Academic Detailing Advisory
Committee, Member of the Maine's Gubernatorial Opioid Response Clinical Advisory Committee,
Member of Lunder-Dineen Time to Ask (about unhealthy drinking) Advisory Committee, Member of the
Board of Directors of the Co-Collaborative Serving Maine
Carol A. Ott, PharmD, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Project ECHO -
Indiana University - Opioid Use Disorders - Expert Panelist, Tippecanoe County (Indiana)
Public Defender's Office - case consultation, Psychopharmacology Consultation Team -
Indiana University - Department of Child Services
Educational Grants, Research Grants or Contracts: Area Health Education Centers -
North Central Indiana, Indiana Clinical and Translational Sciences Institute (CTSI)
Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board,
Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), NAMI West Central Indiana
Chris Paxos, PharmD, BCPP, BCPS, BCGP
Chair and Senior Editor
Associate Professor of Pharmacy Practice
Northeast Ohio Medical University
No Relevant Financial Relationships to Disclose
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.
By continuing to use the site, you agree to this collection.